Abstract
The disparate renal actions of clonidine and 2,6-dimethyl clonidine (2,6-DMC), recently reported by the authors, may be the result of stimulation of alpha-2 adrenoceptors and imidazoline-preferring sites, respectively. Studies found that in one kidney-one clip (1K-1C) hypertension, the density of renal binding sites labeled by [3H] idazoxan (imidazoline-preferring sites) but not [3H] rauwolscine (alpha-2 adrenoceptors) was decreased compared with the 1K control rats. The renal response to 2,6-DMC in 1K-1C hypertensive rats and 1K control rats was compared. In 1K control rats, 2,6-DMC infusion directly into the renal artery (0, 1 and 3 micrograms kg-1 min-1) produced a dose-related increase in the percent fractional excretion of water and sodium and osmolar clearance. This effect was similar to that reported for the imidazoline-preferring site agonist moxonidine. Conversely, in 1K-1C hypertensive rats, these infusion rates of 2,6-DMC failed to alter renal water and solute excretion. By contrast, clonidine (3 micrograms kg-1 min-1) produced a similar increase in the percent fractional excretion of water and sodium, free water clearance and osmolar clearance in 1K-1C hypertensive rats and 1K normotensive rats. In renal membranes from 1K-1C hypertensive rats, [3H] idazoxan binding (imidazoline-preferring site antagonist) was decreased, whereas the binding of [3H] rauwolscine (alpha-2 adrenoceptor antagonist) was unaltered. As proposed in a previous study, the decreased response to 2,6-DMC but not clonidine in 1K-1C hypertensive rats indicates that these two agonists, although structurally similar, are functioning at two unique sites.(ABSTRACT TRUNCATED AT 250 WORDS)
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|